Plasmid pMPl-1 in Escherichia coli L-0 encodes aminoglycoside (AG) 3'-phosphotransferase II [APH(3')-I].
the level of activity of an AG phosphotransferase in these strains lowered their susceptibility to AGs which were substrates for which the enzyme had low Kms. However, an increase in AG-modifying activity alone did not result in large increases in the MICs for poor substrates of the enzyme. In strains which lacked AG-modifying enzymes, a decrease in the rate of AG uptake increased the MICs modestly for a broad spectrum of AGs. When a strain bore the phosphotransferase, a decrease in generalized AG uptake could raise the MIC further, not only for low-Km substrates, but even for AG substrates for which the enzyme had high Kms. Thus, increased modifying activity, together with a diminished rate of uptake, could produce even higher MICs for poor AG substrates.
An aminoglycoside (AG)-modifying enzyme generally confers bacterial resistance to its AG substrates. However, one cannot necessarily correlate quantitatively the level of activity of an AG-modifying enzyme, as determined by an in vitro assay, with the level of resistance for which it is responsible. In order to overcome bacterial resistance that is due to AG-modifying enzymes, semisynthetic derivatives of AGs have been designed so that they are modified enzymatically at much slower rates than the parent compounds. Thus, such semisynthetic AGs may be active against a strain bearing the enzyme which modifies the parent AG. Nonetheless, in some cases substantial enzyme activity may be demonstrated against the semisynthetic AG under in vitro assay conditions (10) . Undoubtedly, the chemical alterations that produce a semisynthetic AG derivative may reduce the affinity of an existing AG-modifying enzyme for the substrate, even though the alteration does not actually block the site of enzymatic attack. Thus, although the enzyme could still modify the new AG, its Km for this substrate might be substantially higher than the Km for the parent compound. Such differences in affinity have been proposed to explain the susceptibility to amikacin of various strains of Staphylococcus aureus that reportedly possess a 3'-phosphotransferase activity for amikacin and other AGs (6) .
Little is known about the mechanisms whereby novel (i.e., previously rare or undetected) types of AG resistance to newly introduced AGs emerge. One possible mechanism for evolution of new AG-modifying activity is the exploitation of existing enzymatic activity that modifies a semisynthetic AG without producing resistance. For example, a mutation that * Corresponding author.
increases production of an AG-modifying enzyme might result in decreased susceptibility to a minor substrate of the enzyme. Alternatively, a mutation might confer resistance to a minor substrate by altering the enzyme so that it increases its affinity (i.e., lowers the Kin) for the AG.
We set out to examine whether mutational effects on AG-modifying enzymes could produce new resistance to recently developed semisynthetic AGs that have not been widely used yet. At the time that our work began, amikacin, a semisynthetic derivative of kanamycin A, was being introduced into clinical use, and existing resistance to amikacin among isolates of aerobic gram-negative bacilli was rare. Thus, we decided to examine the development of amikacin resistance in mutants of a laboratory strain of Escherichia coli by exploiting an AG-modifying enzyme for which amikacin was a minor substrate (23) .
The "rate competition" model of Bryan (3) described the level of resistance exhibited by a bacterial strain as the result of competition between the rate of enzymatic modification of the AG (when a modifying enzyme is present) and the rate of uptake of free active drug into the cytoplasm. This model was formulated on the basis of extensive studies of uptake of dihydrostreptomycin and gentamicin, as well as from limited reports (11) of studies with AG-modifying enzymes.
Unfortunately, there are no reports of experiments which have systematically placed plasmids that govern a range of AG-modifying activities into strains that possess a broad range of rates of AG uptake. The cases presented are limited in their examination of the role of the enzyme. Thus, in terms of effects on AG susceptibility, we cannot derive conclusions regarding the quantitative relationships between the parameters of enzymatic activity (Ki,m Vmax, and total
a See reference 23. Bacterial strains. Tables 1 and 2 list the relevant characteristics of the E. coli strains and plasmids used in this study. Strain W677(pMP1-2, pMP2) is a spontaneous mutant that was selected for amikacip resistance from W677(pMP1-1, pMP2), an amikacin-susceptible strain with a plasmidencoded APH(3')-II that phosphorylates and confers highlevel resistance to kanamycin. Although the APH(3')-II of strain W677(pMP1-1, pMP2) has demonstrable activity for amikacin, strain W677(pMP1-1, pMP2) is amikacin susceptible. Strain W677(pMP1-2, pMP2) has increased APH(3')-II activity against amikacin, as well as against kanamycin and the other substrates of the enzyme. The larger (57-megadalton) plasmids from these strains were conjugated into plasmid-free strain L-O (23) . From strain W677(pMP1-1, pMP2) we selected transconjugant L-O(pMP1-1) by using Preparation of sonic extracts. Sonic extracts were prepared as described previously (27) . After sonication, the suspensions were centrifuged at 12,000 x g for 15 min at 2°C, and the supernatants (sonic extracts) were aspirated and kept on ice. Extracts which were to be assayed for AG phosphorylation were prepared in 0.6 M sodium cacodylate (pH 7.0) or in 0.1 M PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid)] buffer (pH 7.0). The phosphorylating activity in crude extracts was determined by the radioenzymatic phosphocellulose filter binding assay (23) .
Purification of the APH(3')-II gene products from strains
and L-O(pMP3-1) the amikacin phosphorylating activities were purified as follows. Cells (200 g, wet weight) were suspended in 0.1 M PIPES (pH 7.0)-10% glycerol-10 mM P-mercaptoethanol and sonicated. APH(3')-II activities were purified from crude extracts essentially as described by Goldman and Northrop (16) , except that paromomycin-CHSepharose 4B replaced Affi-gel 10 for affinity chromatography.
Determination of enzyme purity. To determine the purity of APH(3')-II, we analyzed samples from various stages of purification on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (10o acrylamide, 2.7% bisacrylamide) by using the method of Laemmli (18) . Gels (16 by 24 mm) were electrophoresed at 60 mA for 5 h. Proteins were visualized by staining with Coomassie brillant blue and destaining in 50% methanol-10% acetic acid. Samples of the APH(3')-II preparations (estimated to be >95% pure from sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels) from strains L-O(pMP3-1) and L-O(pMP4-1) were compared by gel electrophoresis in two dimensions (22) . Protein concentrations were determined by the method of Lowry et al. (19) .
Kinetic analyses of purified APH(3')-II. Kinetic determinations of Km and Vmax for the APH(3')-II from strains L-0(pMP3-1) and L-O(pMP4-1) were made by using the results of a coupled spectrophotometric assay (16) Determination of plasmid copy number. Plasmid copy number was determined by the saturation hybridization method (15) for strain L-O(pMP1-1), strain L4(pMP1-2), and (as a control) strain L-O(pMP4-1), a strain bearing the APH(3')-II gene cloned into pBR322.
Transfer of genetic material. The method used for conjugal transfer of AG resistance has been described previously (23 
RESULTS
Rationale. In a previous study (23) we proposed two possible mechanisms to account for the greater activity of APH(3')-II for amikacin in strain L4(pMP1-2) than in strain L-O(pMP1-1); either a plasmid-borne mutation altered the primary amino acid sequence of the enzyme so that it recognized and phosphorylated amikacin more efficiently, or a plasmid-borne mutation increased the production of unaltered APH(3')-II.
To explore the first possibility, we purified the enzymes derived from the cloned APH(3')-II genes of pMP1-1 and pMP1-2 in order to compare these enzymes for differences in their kinetic properties. We examined the second possible mechanism for greater activity by comparing the plasmid copy numbers in strains L4(pMP1-2) and L-O(pMP1-1).
Purification of APH(3')-II. In the purification of the APH(3')-II PM-CH-Sepharose 4B was used because it has been reported (16) to give greater separation than affinity chromatography with the ligand bound to cyanogen bromide-activated Sepharose 4B alone. We discovered that the PM-CH-Sepharose 4B column behaved as an ion exchanger at salt concentrations below 0.3 M NaCl, at which point the majority of contaminating proteins had been eluted. At 0.7 M NaCl, APH(3')-II activity was eluted from the column. This finding allowed us to use a step gradient for elution of APH(3')-II from the affinity column. Storage of the purified enzyme at 4°C and between pH 8.0 and 9.0 stabilized the activity of the enzyme for further use. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of samples after the various steps in purification of APH(3')-II from strains L-O(pMP3-1) and L-O(pMP4-1) confirmed that the greatest degree of purification in both cases was obtained after affinity chromatography. No contaminating bands were readily observable. We estimated that the molecular weight of APH(3')-II obtained from strains L-O(pMP3-1) and L-O(pMP4-1) was 29,800. Two-dimensional gel electrophoresis of the purified APH(3')-IIs from strains L-O(pMP4-1) and L-O(pMP3-1) did not reveal any differences in migration between the two purified proteins.
Kinetic analyses of purified APH(3')-II We determined the Ki,, the Vmax, and the ratios of Vmax to Km for several substrates of the purified APH(3')-IIs from strains L-0(pMP3-1) and L-0(pMP4-1). Because of the relative insensitivity of the spectrophotometric assay (this assay cannot accurately monitor small differences in activity at substrate concentrations below 10 ,uM), we were unable to calculate the Kms for kanamycin and ribostamycin accurately. On the other hand, the Kms for amikacin and butirosin could be measured by this method (Table 3) , and the values were confirmed by the radioenzymatic phosphocellulose-filter binding assay (data not shown). The values shown in Table 3 are for the enzyme from strain L-0(pMP3-1); the values for the enzyme from strain L-0(pMP4-1) did not differ from these values by more than 5%. The Km of kanamycin for both enzymes was determined to lie in the micromolar range by the radioenzymatic method. In contrast, the Km of amikacin for both enzymes was at least 70 times higher than the Km of kanamycin. For both enzymes, the Kms of ribostamycin and butirosin were slightly higher than the Km of kanamycin. The identical Kms for the two purified enzymes against each AG substrate and for ATP suggested that the enzymes derived from strains L-0(pMP1-1) and L4(pMP1-2) were not different. For both enzymes, the Vmax for amikacin was less than the Vmaxs for the other AG substrates. Because of the great difference in K5s, the ratio of Vmax to Km was much higher for kanamycin than for amikacin. Determination of plasmid copy number. We measured directly the plasmid copy numbers of representative amikacin susceptible and amikacin resistant strains by using the saturation hybridization assay. Since plasmid DNA has a much lower sequence complexity than chromosomal DNA, very little reaction of nonplasmid sequences in the tracer is observed in the presence of sufficient plasmid driver. In these experiments, purified pMPl-1 was used as the driver DNA to determine the plasmid copy numbers in strains L-0(pMP1-1) and L4(pMP1-2), whereas purified pMP4-1 was used as driver DNA for strain L-0(pMP4-1). In calculating the copy number from the results of saturation hybridization experiments, we assumed molecular weights of 57 x 101 for pMPl-1 and pMPl-2, 4.03 x 106 for pMP4-1, and 2.5 x 109
for the E. coli chromosome. The copy numbers which we determined for the plasmids in strains L-0(pMPl-l), L4(pMP1-2), and L-0(pMP4-1) were 1, 2, and 34, respectively. These results are averages from two determinations. The level of recovery of radioactivity from the column was generally 80 to 90% of the input radioactivity, and the tracer background, which was subtracted prior to copy number calculations, rarely exceeded 2.0%o of the tracer input.
Conjugal transfer and transformation without selection in the presence of inhibitory levels of AGs. We considered the possibility that selection with amikacin for plasmid transfer into transconjugant L4(pMP1-2) or for transformants which had acquired the cloned APH(3')-II gene of strain L4(pMP1-2) might have also selected a chromosomal mutation that reduced the susceptibility of these strains to a variety of AGs. To examine this possibility, we again conjugated strain W677(pMP1-2, pMP2) with strain L-0, but we selected transconjugants by using kanamycin or streptomycin rather than amikacin, which was used in the selection of strain L4(pMP1-2). In contrast to strain L4(pMP1-2), the new transconjugants [e.g., strain L-O(pMP1-2)] were susceptible to amikacin (Table 4) . Similarly, in order to avoid selection with an AG, we obtained transformants bearing the APH(3')-II gene of strain L4(pMP1-2) cloned in pBR322 (pMP4-1) by selection with carbenicillin (pBR322 encodes carbenicillin resistance) and screening for resistance to individual AGs. Unlike the earlier transformants (25) selected with amikacin, these transformants [e.g., strain L-O(pMP4-1)] were never exposed to any AG in their selection or maintenance. They remained amikacin susceptible, and the MIC of gentamicin or streptomycin did not increase (Table 4) . Thus, selection for acquisition of a plasmid bearing the APH(3')-II gene by exposure to amikacin in fact resulted in a dramatic increase in the MIC of amikacin. In contrast, selection of the same plasmid with kanamycin or streptomycin or selection for the carbenicillin marker rather than the AG marker on the plasmid failed to produce a significant increase in the MIC of amikacin. From this discrepancy, it seemed that exposure to high concentrations of amikacin might select a mutation that would interact with the plasmidborne mutation that raises APH(3')-II activity, so that this combination would confer high-level resistance to amikacin. We then purposely selected spontaneous AG-resistant mutants from amikacin susceptible transformants and transconjugants that produced APH(3')-II by using concentrations of amikacin, streptomycin, and gentamicin that were above the MICs of these AGs.
Selection of AG-resistant mutants. Spontaneous mutants of strains L-O(pMP1-1) and L-O(pJR66a) (23) were selected in the presence of 12.5 ,ug of amikacin per ml, 200 ,ug of streptomycin per ml, or 3.12 ,ug of gentamicin per ml at a frequency which ranged from 1O-7 to 10-5. Mutants from strains L-O(pMP3-1), L-O(pMP1-2), and L-O(pMP4-1) ap- ,ug of gentamicin per ml. Table 4 shows the susceptibilities of AG-resistant mutants obtained from the amikacin-susceptible strains described above. Mutants selected from the same strain by using the various AGs described above had similar patterns of AG resistance, so only one representative mutant from each strain is shown ( Table 1 ). The MIC of amikacin for each mutant was dramatically higher than the MIC for its parental strain, regardless of which AG was used for selection. The level of resistance increased somewhat more in the strains with the APH(3')-II gene cloned into a multicopy plasmid, such as strains L7(pMP3-1) and L8(pMP4-1), than in the mutants selected from strain L-0(pMP1-1) [e.g., strain L3(pMP1-1), which probably bears a single-copy derivative of pJR66a] (8). The presence of the AG 3"-phosphotransferase [APH(3")] gene produced streptomycin resistance in the parents [e.g., strains L-0(pMP1-1), L-0(pMP1-2), and L-0(pJR66a)] and even higher levels of streptomycin resistance in the mutants that were selected for generalized AG resistance. On the other hand, when the APH(3") gene was lacking, the parent strain was susceptible to streptomycin, and selection for AG resistance resulted in only a modest increase in the MIC of streptomycin. Since all of the transconjugants and transformants lacked any gene for gentamicin modification, the parent strains used for mutant selection were gentamicin susceptible, and the MICs of gentamicin were only modestly higher in the AG-resistant mutants.
All strains were assayed for APH(3')-II activity for amikacin and kanamycin and for APH(3") activity for streptomycin. The only mutant which appeared to have increased its activity compared with its parental strain was strain L5(pMP1-2). This strain doubled its activity against all three substrates (data not shown). We have not ruled out the possibility that this strain may have an increase in plasmid copy number compared with its parent strain.
Curing of plasmids. To investigate the effects of the putative chromosomal mutations in the AG-resistant mutants, we first cured them of their plasmids. Then we could assess the influence of these mutations on the AG resistance of these strains without the additional AG resistance conferred by their plasmid-borne genes.
The plasmids in the following strains were eliminated by exposing the strains to novobiocin: strains L-0(pMP1-1), L4(pMP1-2), L-0(pMP1-2), L-0(pMP4-1), and L8(pMP4-1).
From 2 to 5% of colonies which grew after treatment with novobiocin were susceptible to 50 ,ug of kanamycin per ml, 25 ,ug of streptomycin per ml, and 200 ,ug of carbenicillin per ml. Clones representing cured derivatives of each of the strains were saved. None of these clones possessed AGmodifying enzyme activity. As shown in Table 5 , none of the cured strains retained the high-level AG resistance present in its progenitor strain (Table 4 ). An agarose gel (data not shown) of lysates of the cured strains, as well as of strains L-0 and L-0(pMP4-1), confirmed that there were no plasmids in the lysates from strain L-0 and from the cured strains.
Uptake of 3H-labeled amikacin and 3H-labeled dihydrostreptomycin into cured shains. The rates of uptake of 3H-labeled amikacin and 3H-labeled dihydrostreptomycin into strains which had been cured of their plasmids were measured from three to five times for each strain, and the mean values are shown in Table 5 3H-labeled amikacin uptake and the MIC of amikacin for the with a lower (i.e., less negative) electrical potential, such as strain (Table 5 ); i.e., strains with higher amikacin MICs strain L4, was less susceptible to AGs than a strain with a (strains L4 and L8) took up amikacin less rapidly than strains greater electrical potential, such as strain L-0. that were more susceptible to amikacin [strain L-0, the cured Interaction of AG modification and uptake in determining derivative of strain L-O(pMP1-1), the cured derivative of AG resistance. We wanted to separately assess the contribustrain L-0(pMP1-2), and the cured derivative of tions of changes in AG uptake, of changes in AG-modifying L-O(pMP4-1)], which showed the highest levels of amikacin activity, and of changes in both processes to the level of uptake. The rates of uptake of 3H-labeled dihydrostrep-bacterial AG susceptibility. To do this, we constructed tomycin followed the same pattern as the rates of 3H-labeled strains bearing plasmids that encoded different levels of amikacin uptake among the strains tested. However, the APH(3')-II activity in the backgrounds of a high-AG-uptake range of uptake values was broader for 3H-labeled amikacin E. coli recipient, strain L-0, or a mutant with low AG uptake, than for 3H-labeled dihydrostreptomycin. Nonetheless, strain L4. Table 6 shows the APH(3')-II activities, the rates cured strains with faster rates of 3H-labeled dihydrostrepto-of amikacin and dihydrostreptomycin uptake in the cured mycin uptake (i.e., more than 5.0 ng/mg [dry weight] of background, and the AG susceptibilities of the constructed bacteria per min) were more susceptible to AGs than strains strains. A decrease in the rate of AG uptake was accompawith slower rates of uptake.
nied by increases in the MICs of all of the AGs tested, Electrical potential. We measured the cellular electrical whether or not they were substrates for an AG-modifying potentials for strains L-0 and L4 in order to correlate these enzyme present in the strain. The MIC of each AG (except values with the values for AG uptake and AG susceptibility kanamycin) for strains with the strain L4 background was for these two strains. Strain L-0, the standard E. coli 4-fold to as much as 32-fold higher than the MIC for the AG-susceptible strain with wild-type rates of AG uptake, corresponding strain with the strain L-0 background. If the had an electrical potential of -170 mV; strain L4, the AG was a substrate for which the AG-modifying enzyme had AG-resistant mutant with reduced rates of uptake, had an a low K,,,, then a decrease in AG uptake increased the MIC electrical potential of -139 mV. These values were the of that AG beyond the high-level resistance conferred by the averages of five independent determinations, and no individenzyme alone. When the AG-modifying enzymes were preual measurement differed from the average by more than 5 sent in the strain L4 background, the MICs of the AG mV. Thus, as predicted by Damper and Epstein (7), a strain substrates, kanamycin and streptomycin, were the same to eightfold higher than the already high MICs of kanamycin and streptomycin conferred by these enzymes in the strain L-0 background. If the AG was a high-Km substrate of the AG-modifying enzyme, a decrease in AG uptake increased the MIC of that AG to substantially higher levels than the levels obtained by merely increasing the amount of the AG-modifying enzyme (e.g., by increasing the plasmid copy number). When pMP1-1 was present in the strain L4 background, the MIC of amikacin was 25 jig/ml, which was 32 times the MIC for pMP1-1 in the strain L-0 background and at the generally accepted upper limit of clinical susceptibility. Increasing the APH(3')-II activity in the strain L4 background (e.g., by introducing pMP1-2 or pMP4-1) resulted in a further two-to eightfold increase in the MIC of amikacin, to a level that would seriously impair the therapeutic effectiveness of amikacin. The presence of these plasmids in strain L4 had no effect on the MIC of gentamicin or on the MIC of streptomycin when APH(3') was absent (i.e., with pMP4-1).
DISCUSSION
In this report, we show that the APH(3')-IIs encoded on pMP1-1 and pMP1-2 are not measurably different in their kinetic properties. We also found that the increased APH(3')-II activity associated with pMP1-2 was apparently due to the increased plasmid copy number of pMP1-2 compared with the pMP1-1 copy number. Further support for this conclusion comes from the fact that the streptomycin phosphotransferase [(APH(3")] activity encoded on both plasmids was also higher in strains containing pMPl-2 than in strains containing pMP1-1.
Since there appeared to be no difference in the APH(3')-IIs from transformants that bore the APH(3')-II genes of strains L-0(pMP1-1) and L4(pMP1-2) cloned into pBR322, the structural genes were presumably identical. When the gene of each strain was cloned into the same plasmid, one would expect that the resulting APH(3')-II activities would be similar in transformants bearing either recombinant plasmid, and this was indeed observed. If the relative level of amikacin resistance depends on the amount of APH(3')-II activity alone, then these transformants should exhibit similar levels of amikacin resistance. The finding that clone MP101 (25) , a clone bearing the gene from strain L4(pMP1-2), was more resistant than clone MP61 (25) , a clone with the strain L-0(pMP1-1) gene, was inconsistent with this prediction. This discrepancy suggested that another factor besides the amount of APH(3')-II activity was playing a role in the development of clinically significant levels of amikacin resistance in strain L4(pMP1-2). We investigated the possibility that we had selected chromosomal mutations in generalized AG uptake which thereby affected susceptibility to all AGs. Such a mutation, together with an increase in APH(3')-II activity, might have been responsible for the marked increase in resistance to amikacin.
We set out to examine this possibility by transferring the APH(3')-II gene into strain L-0 but specifically avoiding selection of secondary mutations. In the case of the original plasmid, we selected for acquisition of the APH(3") gene by exposure to streptomycin or for the APH(3')-II gene by exposure to kanamycin (for which the enzyme has a high affinity). For transfer of the recombinant plasmid bearing the APH(3')-II gene, we selected transformants with carbenicillin (whose resistance is encoded by a separate gene on this plasmid). In contrast to strains selected with amikacin, all of these transconjugants and transformants remained amikacin susceptible and exhibited no increases in the MICs of AGs which were not substrates of APH(3')-II. The amikacin MICs for strains L-O(pMP3-1) and L-O(pMP4-1) were identical and were fourfold higher than the amikacin MIC for strain L-0 or L-0(pMP1-1), which had only a single copy of the plasmid. Thus, the increased APH(3')-II activity produced when the gene was borne on a multicopy plasmid conferred a modestly higher MIC; however, a single-copy plasmid encoding APH(3')-II had no discernible effect on the MIC of amikacin. On the other hand, the single-copy plasmid encoding APH(3')-II was sufficient to confer resistance to kanamycin; this correlates with our observation that purified APH(3')-II had a much higher ratio of Vmax to Km for kanamycin than for amikacin.
Thus, we could avoid specifically at the time of transfer of the APH(3')-II gene the selection of chromosomal mutations that produced generalized AG resistance. We then set out systematically to select AG-resistant mutants from the transconjugants and transformants that already contained the APH(3')-II gene but had not been exposed to inhibitory concentrations of AGs and were thus amikacin susceptible. Selection with inhibitory concentrations of various AGs produced mutants which all exhibited a dramatic increase in the MIC of amikacin. Resistance to amikacin developed even in transconjugants that bore a single copy of the APH(3')-II gene. Strains which contained multiple copies of a plasmid bearing the APH(3')-II gene (either from a mutation in the plasmid which increased its copy number or by cloning into a multicopy plasmid, such as pBR322) developed an even higher level of resistance to amikacin because of mutations that modestly raised the MIC of gentamicin, for which no modifying enzyme was present. In conjunction with AG-modifying enzymes, these chromosomal mutations seemed to confer high-level resistance to substrates of the enzymes.
We attempted to characterize the chromosomal mutations in some of the amikacin-resistant strains by measuring AG uptake after these strains were cured of their plasmids. Our uptake results correlated with the AG susceptibilities of many of the cured strains. There are limitations to measuring AG uptake since this requires using drug concentrations that are near or above the MIC. Perhaps it would be more accurate to measure the electrical potential, as determined by the distribution of lipid-soluble phosphonium ions (7) , in all of the cured strains, as there appears to be a correlation between the electrical potential of bacterial cells and their susceptibility to AGs. One could even measure the electric potentials of intact plasmid-bearing strains as an index of AG uptake potential without having to cure the strains before measuring AG uptake.
The data presented in this paper confirmed a number of predictions made by the rate competition model of AG resistance of Bryan's (3). In addition, we found that reduced AG uptake in the presence of APH(3')-II can raise the MIC of amikacin to levels of clinically important resistance, even though the affinity of the enzyme for amikacin is poor. A comparison of strain L4(pMP1-1) with strain L-0(pMP1-1) (Table 6 ) demonstrated that a decrease in AG uptake without a concomitant increase in APH(3')-II activity could raise the MICs not only for low-Km substrates but also for poor substrates, such as amikacin. Furthermore, when a decrease in AG uptake was accompanied by an increase in APH(3')-II activity, the amikacin MICs were raised to even higher levels.
The Bryan rate competition model of AG resistance has been modified (4) to account for evidence (14, 24) (25) that this enzyme is associated not only with resistance to amikacin, but also with resistance to 4'-deoxy-6'-N-methylamikacin (BB-K 311), a derivative of amikacin designed to be free from attack by the two other enzymes known to modify amikacin and thereby confer resistance to it (9) . It is of great interest that mutants with high levels of resistance to amikacin can be selected in strains bearing APH(3')-II by exposing the strains to low levels of an AG such as gentamicin, which is not even a substrate for the enzyme. The ramifications of this finding are striking, since it now appears that it is possible for amikacin-resistant strains to emerge as a result of exposure to relatively low levels of gentamicin, a principal AG used for treatment in hospitals where amikacin use is restricted.
